Carotid artery stenosis surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 15: | Line 15: | ||
understanding of patient preferences. (Level of Evidence: C) | understanding of patient preferences. (Level of Evidence: C) | ||
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]]=== | ===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]]=== | ||
# Except in extraordinary circumstances, carotid revascularization by either CEA or CAS is not recommended when atherosclerosis narrows the lumen by less than 50%. (Level of Evidence: A) | # Except in extraordinary circumstances, carotid revascularization by either CEA or CAS is not recommended when atherosclerosis narrows the lumen by less than 50%. (Level of Evidence: A) | ||
# Carotid revascularization is not recommended for patients with chronic total occlusion of the targeted carotid artery. (Level of Evidence: C) | # Carotid revascularization is not recommended for patients with chronic total occlusion of the targeted carotid artery. (Level of Evidence: C) | ||
Line 29: | Line 28: | ||
}} | }} | ||
==Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Periprocedural Management of Patients Undergoing Carotid Endarterectomy<ref name="pmid21282505">{{cite journal| author=Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL et al.| title=2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. | journal=Circulation | year= 2011 | volume= 124 | issue= 4 | pages= 489-532 | pmid=21282505 | doi=10.1161/CIR.0b013e31820d8d78 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21282505 }} </ref> (DO NOT EDIT)== | |||
{{cquote| | |||
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]=== | |||
# Aspirin (81 to 325 mg daily) is recommended before CEA and may be continued indefinitely postoperatively. (Level of Evidence: A) | |||
# Beyond the first month after CEA, aspirin (75 to 325 mg daily), clopidogrel (75 mg daily), or the combination of low-dose aspirin plus extended-release dipyridamole (25 and 200 mg twice daily, respectively) should be administered for long-term prophylaxis against ischemic cardiovascular events. (Level of Evidence: B) | |||
# Administration of antihypertensive medication is recommended as needed to control blood pressure before and after CEA. (Level of Evidence: C) | |||
# The findings on clinical neurological examination should be documented within 24 hours before and after CEA. (Level of Evidence: C) | |||
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]=== | |||
# Patch angioplasty can be beneficial for closure of the arteriotomy after CEA.62,63 (Level of Evidence: B) | |||
# Administration of statin lipid-lowering medication for prevention of ischemic events is reasonable for patients who have undergone CEA irrespective of serum lipid levels, although the optimum agent and dose and the efficacy for prevention of restenosis have not been established. (Level of Evidence: B) | |||
# Noninvasive imaging of the extracranial carotid arteries is reasonable 1 month, 6 months, and annually after CEA to assess patency and exclude the development of new or contralateral lesions. Once stability has been established over an extended period, surveillance at longer intervals may be appropriate. Termination of surveillance is reasonable when the patient is no longer a candidate for intervention. (Level of Evidence: C) | |||
}} | |||
==Surgery== | ==Surgery== | ||
*[[Carotid endarterectomy]] (surgical removal of the atheroma) | *[[Carotid endarterectomy]] (surgical removal of the atheroma) |
Revision as of 14:30, 2 October 2012
Carotid artery stenosis Microchapters |
Diagnosis |
---|
Treatment |
ACC/AHA Guideline Recommendations |
Periprocedural Management of Patients Undergoing Carotid Endarterectomy |
Atherosclerotic Risk Factors in Patients With Vertebral Artery Disease |
Occlusive Disease of the Subclavian and Brachiocephalic Arteries |
Case Studies |
Carotid artery stenosis surgery On the Web |
American Roentgen Ray Society Images of Carotid artery stenosis surgery |
Risk calculators and risk factors for Carotid artery stenosis surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Selection of Patients for Carotid Revascularization[1] (DO NOT EDIT)
“ |
Class I
understanding of patient preferences. (Level of Evidence: C) Class III
Class IIa
Class IIb
|
” |
Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Periprocedural Management of Patients Undergoing Carotid Endarterectomy[1] (DO NOT EDIT)
“ |
Class I
Class IIa
|
” |
Surgery
- Carotid endarterectomy (surgical removal of the atheroma)
- Carotid stenting
References
- ↑ 1.0 1.1 Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL; et al. (2011). "2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery". Circulation. 124 (4): 489–532. doi:10.1161/CIR.0b013e31820d8d78. PMID 21282505.